Cindy Yeung, DO
General Practice · Piscataway, NJNPI 1356356141
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $109,616 of the $110,639 with a category attached, or 99.1%. Otsuka Pharmaceutical Development & Commercialization, Inc. accounts for 99.7% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2020 at $110,281 and has fallen 99.8% since, to $229 in 2025. Among general practice clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 29 payments — averaging $3815.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$110K
- Neurocrine Biosciences, Inc.$123
- AbbVie$106
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$101
- Alkermes, Inc.$29
What the payments were for
- Consulting fees$109,61699%
- Travel & lodging$5581%
- Food & beverage$4650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 24 | $110,281 |
| Neurocrine Biosciences, Inc. | 1 | $123 |
| AbbVie | 1 | $106 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $101 |
| Alkermes, Inc. | 2 | $29 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ABILIFY MAINTENA$109,616
- REXULTI$109,616
- ABILIFY MYCITE$83,055
- INGREZZA$123
- VRAYLAR$106
- CAPLYTA$101
How this compares
$110,639 in reported general payments places this provider in the 95th percentile of 2,978 general practice providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aripiprazole | 89 | $3,846 |
| Varenicline Tartrate | 14 | $3,396 |
| Paliperidone ErPaliperidone | 35 | $2,715 |
| Buspirone Hcl | 140 | $2,673 |
| Clozapine | 48 | $2,047 |
| Naltrexone Hcl | 40 | $1,431 |
| Prazosin Hcl | 77 | $1,420 |
| Chlorpromazine Hcl | 20 | $1,349 |
| Trazodone Hcl | 81 | $1,255 |
| Divalproex Sodium ErDivalproex Sodium | 20 | $1,107 |
| Divalproex Sodium | 24 | $990 |
| Quetiapine Fumarate | 67 | $824 |
| Oxcarbazepine | 16 | $572 |
| Carbamazepine ErCarbamazepine | 13 | $556 |
| Duloxetine Hcl | 34 | $496 |
Paid to pharmacies, not to this prescriber.
Other general practice in Piscataway
- Ryan LakeClark$914K
- Hua-Yu Steven LiaoLodi$816K
- Howard GlazerFort Lee$636K
- Jeffrey ChustckieSomerset$165K
- John MinichettiEnglewood$142K
- Narenderan RajanHackettstown$135K
- Andrew SpectorHaworth$75K
- Paul GoodmanPennington$42K
- Steven RasnerBridgeton$35K
- Penelope ChangTenafly$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.